| Company Name: |
Energy Chemical |
| Tel: |
400-0056266 |
| Email: |
sales8178@energy-chemical.com |
- Tolfenamic Acid
-
-
2026-09-01
- CAS:13710-19-5
- Min. Order: 1Kg
- Purity: 99%
- Supply Ability: 10kg
- Tolfenamic acid
-
- $200.00
-
2026-08-21
- CAS:13710-19-5
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20Tons
|
| | Tolfenamic acid Basic information |
| | Tolfenamic acid Chemical Properties |
| Melting point | 210-214°C | | Boiling point | 405.4±40.0 °C(Predicted) | | density | 1.2037 (rough estimate) | | refractive index | 1.5270 (estimate) | | storage temp. | 2-8°C | | solubility | Practically insoluble in water, soluble in dimethylformamide, sparingly soluble in ethanol and in methylene chloride. It dissolves in dilute solutions of alkali hydroxides. | | pka | 3.66±0.36(Predicted) | | form | Solid | | color | White to Off-White | | Water Solubility | Soluble in water (slightly), acetone (~10 mg/ml), DMSO (52 mg/ml at 25°C), methanol (~10 mg/ml) and ethanol (50 mg/ml). | | Merck | 14,9513 | | Major Application | forensics and toxicology
pharmaceutical (small molecule) | | InChI | InChI=1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18) | | InChIKey | YEZNLOUZAIOMLT-UHFFFAOYSA-N | | SMILES | C(O)(=O)C1=CC=CC=C1NC1=CC=CC(Cl)=C1C | | CAS DataBase Reference | 13710-19-5(CAS DataBase Reference) | | EPA Substance Registry System | Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]- (13710-19-5) |
| Hazard Codes | Xn | | Risk Statements | 22 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | RTECS | CB2687500 | | HazardClass | 6.1 | | PackingGroup | III | | HS Code | 29224919 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral |
| | Tolfenamic acid Usage And Synthesis |
| Chemical Properties | White Solid | | Uses | antiinflammatory, analgesia | | Uses | Amidated GRF fragment equipotent to GRF in release of somatotropin from anterior pituitary | | Uses | A non steroidal anti-inflammatory agent found to inhibit COX-2 isoenzymes | | Uses | Tolfenamic acid is a non-steroidal anti-inflammatory agent. It interferes with synthesis of β-amyloid precursor protein, and thus Aβ peptides, by promoting degradation of an essential transcription factor. It inhibits fMLP- and A23187-induced Ca2+ influx in human PMNL with an IC50 value of approximately 20 μM. | | Uses | Non-steroidal anti-inflammatory drugs (NSAIDs). | | Definition | ChEBI: An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 3-chloro-2-methylphenyl group. Tolfenamic acid is used specifically for relieving the pain of migraine. It also shows anticancer activity. | | General Description | Tolfenamic Acid is an anthranilic acid derivative and a non-steroidal anti-inflammatory drug (NSAID). Its applications in treating pancreatic, esophageal, colorectal and lung cancer is being investigated. | | Biochem/physiol Actions | Non-steroidal anti-inflammatory agent. Interferes with synthesis of β-amyloid precursor protein, and thus Aβ peptides, by promoting degradation of an essential transcription factor. | | Clinical Use | NSAID:
Treatment of migraine | | Synthesis | Tolfenamic acid is obtained by
condensation of 2-chlorobenzoic acid with 3-
chloro-2-methyl-phenylamine using CuBr2 in
diethylenglycol dimethyl ether .
 | | Veterinary Drugs and Treatments | Tolfenamic acid may be useful for the treatment of acute or chronic
pain and/or inflammation in dogs and acute pain/inflammation in
cats. In Europe, it is also approved for use in cattle. | | Drug interactions | Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists:
antagonism of hypotensive effect; increased risk of
nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more
NSAIDs, including aspirin (increased side effects);
avoid with ketorolac (increased risk of side effects
and haemorrhage).
Antibacterials: possibly increased risk of convulsions
with quinolones.
Anticoagulants: effects of coumarins and
phenindione enhanced; possibly increased risk of
bleeding with heparins, dabigatran and edoxaban.
Antidepressants: increased risk of bleeding with
SSRIs and venlafaxine.
Antidiabetic agents: effects of sulphonylureas enhanced.
Antiepileptics: possibly increased phenytoin
concentration.
Antivirals: increased risk of haematological toxicity
with zidovudine; concentration possibly increased by
ritonavir.
Ciclosporin: may potentiate nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate;
increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity;
antagonism of diuretic effect; hyperkalaemia with
potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity | | Metabolism | Tolfenamic acid is metabolised in the liver; the metabolites and unchanged drug are conjugated with glucuronic acid. About 90
% of an ingested dose is excreted in the urine and the remainder in the faeces. | | References | [1] Patent: CN104557584, 2016, B. Location in patent: Paragraph 0016; 0017; 0018 |
| | Tolfenamic acid Preparation Products And Raw materials |
|